

IKK 16

Catalog No: **tcsc1282**



Available Sizes

Size: 10mg

Size: 50mg



Specifications

CAS No:

873225-46-8

Formula:

$C_{28}H_{29}N_5OS$

Pathway:

Autophagy;NF-κB

Target:

LRRK2;IKK

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 27 mg/mL (55.83 mM)

Observed Molecular Weight:

483.63

Product Description

IKK 16 is a selective IκB kinase (**IKK**) inhibitor for **IKK2**, **IKK complex** and **IKK1** with **IC₅₀**s of 40 nM, 70 nM and 200 nM, respectively. IKK16 also inhibits leucine-rich repeat kinase-2 (**LRRK2**) with an **IC₅₀** of 50 nM.


IC50 & Target: IC50: 40 nM (IKK2), 70 nM (IKK complex), 200 nM (IKK1)^[1]

IC₅₀: 50 nM (LRRK2)^[2]

In Vitro: IKK 16 is a potent inhibitor of IKK2 with IC₅₀ value of 40 nM^[1]. IKK 16, a leucine-rich repeat kinase-2 (LRRK2) kinase inhibitor, exhibits in vitro IC₅₀s of 50 nM. IKK 16 exhibits sub-micromolar IC₅₀ concentrations for LRRK2 in vitro, which is lower than what observed for cellular inhibition of Ser935 phosphorylation. IKK 16 (20 μM) can inhibit LRRK2 Ser935 phosphorylation in HEK293 GFP-LRRK2

G2019S cells (GS) or A2016T/G2019S (IRM) cells in vitro.

In Vivo: IKK 16 also demonstrates significant in vivo activity in an acute model of cytokine release. Both routes of administration of IKK 16 (30 mg/kg, sc) or orally (30 mg/kg, p.o) at the indicated dose results in a significant inhibition of 86% (sc) and 75% (p.o.). IKK 16(10 mg/kg, sc) is also active in the thioglycollate-induced peritonitis model in the mouse. The maximal inhibition of neutrophil extravasation in this model is about 50%^[1]. Treatment of septic mice with IKK 16 (1 mg/kg body weight i.v.) results in a significantly increased degree of phosphorylation (P[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!